Oncology
Oncology treatment decision-making is complex, and this has been amplified year on year as the market expands with new approvals/indications.
ONCOLOGY PORTFOLIO
As recent approvals focus on personalized treatment, the market is further challenged to achieve the ever-present need to balance between treatment efficacy and tolerability, while also considering the increased financial toxicity that these new offerings may create.
Our oncology evidence provides insight and understanding of the real-world impact of new drugs on treatment patterns, highlighting the healthcare resource utilization of oncology patients and assessing patients’ quality of life as they live with the disease.
As recent approvals focus on personalized treatment, the market is further challenged to achieve the ever-present need to balance between treatment efficacy and tolerability, while also considering the increased financial toxicity that these new offerings may create.
Our oncology evidence provides insight and understanding of the real-world impact of new drugs on treatment patterns, highlighting the healthcare resource utilization of oncology patients and assessing patients’ quality of life as they live with the disease.
THERAPY AREAS
Extensive therapeutic experience built up over 25 years of heritage in conducting Disease Specific Programmes™, now in over 100 therapy areas.
AUTOIMMUNE
RARE DISEASE
CVRM
CNS
RESPIRATORY
WOMEN’S HEALTH
OPHTHALMOLOGY